Drugs in Dev. Infections and Infectious Diseases
Phase I/ Phase II
China 
Lead Product(s) : SIR0365
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Gaorong Capital
Deal Size : $200.0 million
Deal Type : Series B Financing
Sironax Announces Closing of $200 Million Series B Financing
Details : Sironax plans to use the proceeds to support the ongoing clinical development of its portfolio of receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitors in addition to the continued expansion of its R&D footprint and pipeline including...
Product Name : SIR0365
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 08, 2022
Lead Product(s) : SIR0365
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Gaorong Capital
Deal Size : $200.0 million
Deal Type : Series B Financing
Lead Product(s) : Ad5-nCoV
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
China Is Starting Clinical Trials of A Covid Vaccine that Can Be Inhaled
Details : China’s CanSino Biologics will start clinical trials for a Covid-19 vaccine (Ad5-nCoV) administered through inhalation. Efficacy rates for China’s Covid vaccines have been found to be lower than those developed by Pfizer-BioNTech and Moderna.
Product Name : Ad5-nCoV
Product Type : Vaccine
Upfront Cash : Inapplicable
April 20, 2021
Lead Product(s) : Ad5-nCoV
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ad5-nCoV
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CanSinoBIO Gets China Nod For inhaled COVID-19 Vaccine Trial
Details : CanSino Biologics' COVID-19 vaccine candidate is a recombinant adenovirus vaccine named Ad5-nCoV, co-developed by Chinese biopharmaceutical firm CanSino Biologics and a team led by Chinese military infectious disease expert.
Product Name : Ad5-nCoV
Product Type : Vaccine
Upfront Cash : Inapplicable
March 23, 2021
Lead Product(s) : Ad5-nCoV
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Inactivated Vero Cell
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sinovac COVID-19 Vaccine Appears Safe, Triggers Antibodies in Trial in Children: Researcher
Details : The antibody levels triggered by Sinovac’s CoronaVac were higher than those seen in adults aged 18 to 59 and in elderly people in earlier clinical trials, Zeng said in the presentation.
Product Name : CoronaVac
Product Type : Vaccine
Upfront Cash : Inapplicable
March 22, 2021
Lead Product(s) : Inactivated Vero Cell
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Plonmarlimab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : I-Mab got by the U.S.FDA to conduct a Phase I clinical trial to assess its investigational product TJM2 to treat cytokine release syndrome associated with severe illness caused by COVID-19.
Product Name : TJM2
Product Type : Antibody
Upfront Cash : Inapplicable
December 04, 2020
Lead Product(s) : Plonmarlimab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BBIBP-CorV
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
COVID-19 Vaccine from China's Sinopharm Clears Animal Tests
Details : The vaccine candidate, dubbed BBIBP-CorV and made from an inactivated form of the virus, induced high levels of neutralizing antibodies against SARS-CoV-2—the virus behind COVID-19—in rodents, rabbits and monkeys without triggering any serious advers...
Product Name : BBIBP-CorV
Product Type : Vaccine
Upfront Cash : Inapplicable
November 06, 2020
Lead Product(s) : BBIBP-CorV
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Inactivated Vero Cell
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Inactivated COVID-19 vaccine candidate "CoronaVac” is now approved by the National Medical Products Administration (NMPA) for clinical trial in adolescents and children. Vaccine to be tested in adolescents and children between the ages of 3-17 years o...
Product Name : CoronaVac
Product Type : Vaccine
Upfront Cash : Inapplicable
September 23, 2020
Lead Product(s) : Inactivated Vero Cell
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Plonmarlimab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Data monitoring committee (DMC) reviewed the clinical data and unanimously recommended proceeding to part 2 of the study and endorsed the change of low dose treatment arm (3mg/kg) to high dose (6mg/kg).
Product Name : TJM2
Product Type : Antibody
Upfront Cash : Inapplicable
May 28, 2020
Lead Product(s) : Plonmarlimab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PiCoVacc
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sinovac’s PiCoVacc Experimental Vaccine Shows Promise in Monkeys Infected with SARS-CoV-2
Details : Study will evaluate the safety, tolerance, and preliminary immunogenicity of the Sinovac's SARS-CoV-2 vaccine by vaccinating 144 healthy adults, with two different dosages of the vaccine candidate.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
April 24, 2020
Lead Product(s) : PiCoVacc
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Inactivated SARS-CoV-2 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : This study is to evaluate the safety, tolerance, and preliminary immunogenicity of the Company’s SARS-CoV-2 vaccine by vaccinating healthy adults, with two different dosages of the vaccine candidate.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
April 17, 2020
Lead Product(s) : Inactivated SARS-CoV-2 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
